课题基金 / 基金详情

Next generation patient-derived, genetically-defined kidney and bladder cancer xenograft models for anti-cancer drug development

Next generation patient-derived, genetically-defined kidney and bladder cancer xenograft models for anti-cancer drug development
用于抗癌药物开发的下一代源自患者、基因定义的肾癌和膀胱癌异种移植模型
批准号:
324703
负责人:
Wang Yuzhuo
金额:
$35.68万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2015
资助国家:
加拿大
项目状态:
已结题
起止时间:
2015-03-01 至 2019-03-01

项目摘要

项目成果

Wang Yuzhuo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Over 13 thousand people are diagnosed with kidney (5,900) and bladder (7,900) cancers each year and more than 36 hundred patients die of these cancers annually (1,750 and 1,900 respectively) in Canada. New effective drugs to treat late-staged kidney and b
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A master transcription factor driving cell lineage reprogramming in neuroendocrine prostate cancer development and progression
  • 批准号:
    472404
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2022
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
Optimization and Validation of MCT4-targeting Small Molecule Inhibitors for Treatment of Advanced Cancers
  • 批准号:
    451866
  • 项目类别:
    Operating Grants
  • 资助金额:
    $83.6万
  • 财政年份:
    2021
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
The role of PRDM16 in neuroendocrine prostate cancer development and aggressiveness
  • 批准号:
    420178
  • 项目类别:
    Operating Grants
  • 资助金额:
    $55.73万
  • 财政年份:
    2020
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
Function and therapeutic potential of SUV420H2 in neuroendocrine prostate cancer
  • 批准号:
    390460
  • 项目类别:
    Operating Grants
  • 资助金额:
    $69.66万
  • 财政年份:
    2018
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
海外基金